YS Biopharma Co Ltd
NASDAQ:LSB
US |
Johnson & Johnson
NYSE:JNJ
|
Pharmaceuticals
|
|
US |
Berkshire Hathaway Inc
NYSE:BRK.A
|
Financial Services
|
|
US |
Bank of America Corp
NYSE:BAC
|
Banking
|
|
US |
Mastercard Inc
NYSE:MA
|
Technology
|
|
US |
Abbvie Inc
NYSE:ABBV
|
Biotechnology
|
|
US |
Pfizer Inc
NYSE:PFE
|
Pharmaceuticals
|
|
US |
Palantir Technologies Inc
NYSE:PLTR
|
Technology
|
|
US |
Nike Inc
NYSE:NKE
|
Textiles, Apparel & Luxury Goods
|
|
US |
Visa Inc
NYSE:V
|
Technology
|
|
CN |
Alibaba Group Holding Ltd
NYSE:BABA
|
Retail
|
|
US |
3M Co
NYSE:MMM
|
Industrial Conglomerates
|
|
US |
JPMorgan Chase & Co
NYSE:JPM
|
Banking
|
|
US |
Coca-Cola Co
NYSE:KO
|
Beverages
|
|
US |
Realty Income Corp
NYSE:O
|
Real Estate
|
|
US |
Walt Disney Co
NYSE:DIS
|
Media
|
|
US |
PayPal Holdings Inc
NASDAQ:PYPL
|
Technology
|
Utilize notes to systematically review your investment decisions. By reflecting on past outcomes, you can discern effective strategies and identify those that underperformed. This continuous feedback loop enables you to adapt and refine your approach, optimizing for future success.
Each note serves as a learning point, offering insights into your decision-making processes. Over time, you'll accumulate a personalized database of knowledge, enhancing your ability to make informed decisions quickly and effectively.
With a comprehensive record of your investment history at your fingertips, you can compare current opportunities against past experiences. This not only bolsters your confidence but also ensures that each decision is grounded in a well-documented rationale.
Do you really want to delete this note?
This action cannot be undone.
52 Week Range |
3.06
10.3
|
Price Target |
|
We'll email you a reminder when the closing price reaches USD.
Choose the stock you wish to monitor with a price alert.
Johnson & Johnson
NYSE:JNJ
|
US | |
Berkshire Hathaway Inc
NYSE:BRK.A
|
US | |
Bank of America Corp
NYSE:BAC
|
US | |
Mastercard Inc
NYSE:MA
|
US | |
Abbvie Inc
NYSE:ABBV
|
US | |
Pfizer Inc
NYSE:PFE
|
US | |
Palantir Technologies Inc
NYSE:PLTR
|
US | |
Nike Inc
NYSE:NKE
|
US | |
Visa Inc
NYSE:V
|
US | |
Alibaba Group Holding Ltd
NYSE:BABA
|
CN | |
3M Co
NYSE:MMM
|
US | |
JPMorgan Chase & Co
NYSE:JPM
|
US | |
Coca-Cola Co
NYSE:KO
|
US | |
Realty Income Corp
NYSE:O
|
US | |
Walt Disney Co
NYSE:DIS
|
US | |
PayPal Holdings Inc
NASDAQ:PYPL
|
US |
This alert will be permanently deleted.
Intrinsic Value
The intrinsic value of one LSB stock under the Base Case scenario is 3.48 USD. Compared to the current market price of 3.06 USD, YS Biopharma Co Ltd is Undervalued by 12%.
The Intrinsic Value is calculated as the average of DCF and Relative values:
Valuation Backtest
YS Biopharma Co Ltd
Uncover deeper insights with the Valuation Backtest. Learn how current stock valuations stack up against historical averages to gauge true investment potential.
Start backtest now and learn if your stock is truly undervalued or overvalued!
Stock is trading at its lowest valuation over the past 5 years.
To access the results of this valuation backtest, please register an account with us. Registration is quick and gives you instant access to insights on 3 stocks per week for free.
The backtest for LSB cannot be conducted due to limitations such as insufficient data or other constraints. Please select a different stock or adjust your settings.
Fundamental Analysis
Select up to 3 indicators:
Select up to 3 indicators:
Months
Months
Months
Months
Select up to 2 periods:
Revenue & Expenses Breakdown
YS Biopharma Co Ltd
Balance Sheet Decomposition
YS Biopharma Co Ltd
Current Assets | 903.2m |
Cash & Short-Term Investments | 246.4m |
Receivables | 444.2m |
Other Current Assets | 212.7m |
Non-Current Assets | 609.9m |
PP&E | 480.6m |
Intangibles | 71.2m |
Other Non-Current Assets | 58m |
Current Liabilities | 802.2m |
Accounts Payable | 67.8m |
Accrued Liabilities | 413.9m |
Other Current Liabilities | 320.6m |
Non-Current Liabilities | 125.6m |
Long-Term Debt | 99m |
Other Non-Current Liabilities | 26.6m |
Earnings Waterfall
YS Biopharma Co Ltd
Revenue
|
573.4m
CNY
|
Cost of Revenue
|
-117.7m
CNY
|
Gross Profit
|
455.7m
CNY
|
Operating Expenses
|
-744.1m
CNY
|
Operating Income
|
-288.4m
CNY
|
Other Expenses
|
-145m
CNY
|
Net Income
|
-433.5m
CNY
|
Free Cash Flow Analysis
YS Biopharma Co Ltd
CNY | |
Free Cash Flow | CNY |
LSB Profitability Score
Profitability Due Diligence
YS Biopharma Co Ltd's profitability score is 21/100. The higher the profitability score, the more profitable the company is.
Score
YS Biopharma Co Ltd's profitability score is 21/100. The higher the profitability score, the more profitable the company is.
LSB Solvency Score
Solvency Due Diligence
YS Biopharma Co Ltd's solvency score is 40/100. The higher the solvency score, the more solvent the company is.
Score
YS Biopharma Co Ltd's solvency score is 40/100. The higher the solvency score, the more solvent the company is.
Wall St
Price Targets
LSB Price Targets Summary
YS Biopharma Co Ltd
According to Wall Street analysts, the average 1-year price target for LSB is 3.16 USD with a low forecast of 3.13 USD and a high forecast of 3.26 USD.
Dividends
Current shareholder yield for LSB is .
Shareholder yield represents the total return a company provides to its shareholders, calculated as the sum of dividend yield, buyback yield, and debt paydown yield. What is shareholder yield?
Profile
Country
Industry
Market Cap
Dividend Yield
Description
YS Biopharma Co. Ltd. operates as a biopharmaceutical company, which is dedicated to discovering, developing, manufacturing and commercializing new generations of vaccines and therapeutic biologics for infectious diseases and cancer. The company is headquartered in Beijing, Beijing. The firm's vaccine product YSJATM rabies vaccine has been commercialized. The firm also has four product candidates under various clinical development stages, including PIKA rabies vaccine, PIKA recombinant COVID-19 vaccine, PIKA YS-ON-001 and PIKA YS-HBV-001, and four preclinical stage product candidates, targeting HBV, influenza and cancer with enormous medical demand. In addition, the Company is working on a series of therapeutic targets, rabies and products at the discovery stage.
Contact
IPO
Employees
Officers
The intrinsic value of one LSB stock under the Base Case scenario is 3.48 USD.
Compared to the current market price of 3.06 USD, YS Biopharma Co Ltd is Undervalued by 12%.